Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

324 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.
Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde AL, Jessen F, Hoessler YC, Sanhai WR, Zetterberg H, Woodcock J, Blennow K. Hampel H, et al. Among authors: herholz k. Nat Rev Drug Discov. 2010 Jul;9(7):560-74. doi: 10.1038/nrd3115. Nat Rev Drug Discov. 2010. PMID: 20592748 Review.
Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline.
Lista S, Molinuevo JL, Cavedo E, Rami L, Amouyel P, Teipel SJ, Garaci F, Toschi N, Habert MO, Blennow K, Zetterberg H, O'Bryant SE, Johnson L, Galluzzi S, Bokde AL, Broich K, Herholz K, Bakardjian H, Dubois B, Jessen F, Carrillo MC, Aisen PS, Hampel H. Lista S, et al. Among authors: herholz k. J Alzheimers Dis. 2015 Sep 24;48 Suppl 1:S171-91. doi: 10.3233/JAD-150202. J Alzheimers Dis. 2015. PMID: 26402088 Review.
Association of cerebrospinal fluid α-synuclein with total and phospho-tau181 protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers.
Vergallo A, Bun RS, Toschi N, Baldacci F, Zetterberg H, Blennow K, Cavedo E, Lamari F, Habert MO, Dubois B, Floris R, Garaci F, Lista S, Hampel H; INSIGHT-preAD study group; Alzheimer Precision Medicine Initiative (APMI). Vergallo A, et al. Alzheimers Dement. 2018 Dec;14(12):1623-1631. doi: 10.1016/j.jalz.2018.06.3053. Epub 2018 Jul 26. Alzheimers Dement. 2018. PMID: 30055132 Free article.
Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers.
Frisoni GB, Boccardi M, Barkhof F, Blennow K, Cappa S, Chiotis K, Démonet JF, Garibotto V, Giannakopoulos P, Gietl A, Hansson O, Herholz K, Jack CR Jr, Nobili F, Nordberg A, Snyder HM, Ten Kate M, Varrone A, Albanese E, Becker S, Bossuyt P, Carrillo MC, Cerami C, Dubois B, Gallo V, Giacobini E, Gold G, Hurst S, Lönneborg A, Lovblad KO, Mattsson N, Molinuevo JL, Monsch AU, Mosimann U, Padovani A, Picco A, Porteri C, Ratib O, Saint-Aubert L, Scerri C, Scheltens P, Schott JM, Sonni I, Teipel S, Vineis P, Visser PJ, Yasui Y, Winblad B. Frisoni GB, et al. Among authors: herholz k. Lancet Neurol. 2017 Aug;16(8):661-676. doi: 10.1016/S1474-4422(17)30159-X. Epub 2017 Jul 11. Lancet Neurol. 2017. PMID: 28721928 Review.
Effect of Alzheimer's disease risk and protective factors on cognitive trajectories in subjective memory complainers: An INSIGHT-preAD study.
Teipel SJ, Cavedo E, Lista S, Habert MO, Potier MC, Grothe MJ, Epelbaum S, Sambati L, Gagliardi G, Toschi N, Greicius MD, Dubois B, Hampel H; INSIGHT-preAD study group; Alzheimer Precision Medicine Initiative (APMI). Teipel SJ, et al. Alzheimers Dement. 2018 Sep;14(9):1126-1136. doi: 10.1016/j.jalz.2018.04.004. Epub 2018 May 21. Alzheimers Dement. 2018. PMID: 29792873
Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study.
Sakr FA, Grothe MJ, Cavedo E, Jelistratova I, Habert MO, Dyrba M, Gonzalez-Escamilla G, Bertin H, Locatelli M, Lehericy S, Teipel S, Dubois B, Hampel H; for the INSIGHT-preAD study group; Alzheimer Precision Medicine Initiative (APMI). Sakr FA, et al. Alzheimers Res Ther. 2019 Jan 31;11(1):15. doi: 10.1186/s13195-019-0466-3. Alzheimers Res Ther. 2019. PMID: 30704537 Free PMC article.
The Alzheimer Precision Medicine Initiative.
Hampel H, Vergallo A, Perry G, Lista S; Alzheimer Precision Medicine Initiative (APMI). Hampel H, et al. J Alzheimers Dis. 2019;68(1):1-24. doi: 10.3233/JAD-181121. J Alzheimers Dis. 2019. PMID: 30814352 Review.
Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease.
Vergallo A, Mégret L, Lista S, Cavedo E, Zetterberg H, Blennow K, Vanmechelen E, De Vos A, Habert MO, Potier MC, Dubois B, Neri C, Hampel H; INSIGHT-preAD study group; Alzheimer Precision Medicine Initiative (APMI). Vergallo A, et al. Alzheimers Dement. 2019 Jun;15(6):764-775. doi: 10.1016/j.jalz.2019.03.009. Epub 2019 May 18. Alzheimers Dement. 2019. PMID: 31113759
MiRNA-15b and miRNA-125b are associated with regional Aβ-PET and FDG-PET uptake in cognitively normal individuals with subjective memory complaints.
Vergallo A, Lista S, Zhao Y, Lemercier P, Teipel SJ, Potier MC, Habert MO, Dubois B, Lukiw WJ, Hampel H; INSIGHT-preAD study group; Alzheimer Precision Medicine Initiative (APMI). Vergallo A, et al. Transl Psychiatry. 2021 Jan 27;11(1):78. doi: 10.1038/s41398-020-01184-8. Transl Psychiatry. 2021. PMID: 33504764 Free PMC article.
324 results